Wockhardt to Self-Commercialize Zaynich, Aiming for Greater Value Retention
Wockhardt opts for self-commercialisation of Zaynich over licensing to maximise value: Chairman
Image: Moneycontrol
Wockhardt, led by chairman Habil Khorakiwala, will independently commercialize its antibiotic Zaynich in the US rather than licensing it to a global firm. This strategy aims to maximize product value and support future drug launches, with expected revenues starting in FY28.
- 01Wockhardt is opting for self-commercialization of Zaynich in the US, a shift from the common licensing model used by Indian pharmaceutical firms.
- 02Zaynich, designed to combat drug-resistant infections, has received approvals in India and the US, with a US launch planned within six to eight months.
- 03The drug's US pricing is projected between $10,000 and $15,000 for a treatment course, while it will be significantly cheaper in India.
- 04Khorakiwala estimates global peak sales for Zaynich could reach $1.5 billion to $2 billion annually.
- 05The company is undergoing a transformation to build an innovation-led business model, with plans to support future products using the same commercial structure.
Advertisement
In-Article Ad
Wockhardt, under the leadership of chairman Habil Khorakiwala, has decided to self-commercialize its novel antibiotic Zaynich in the United States, diverging from the typical licensing strategy favored by many Indian pharmaceutical companies. This approach aims to retain more value from the product and establish a foundation for future drug launches. Zaynich, which targets drug-resistant infections, has already secured approvals in India and the US, with a launch anticipated in the US within six to eight months. The drug is expected to be priced between $10,000 and $15,000 for a treatment course in the US, significantly lower in India. Khorakiwala projects the global peak sales potential of Zaynich at $1.5 billion to $2 billion annually. The company is building a comprehensive commercial structure, including in-house leadership for medical, sales, and marketing functions, while outsourcing operational tasks. This strategic shift aligns with Wockhardt's broader goal of creating an innovation-driven business model, which will support the launch of additional products from its pipeline.
Advertisement
In-Article Ad
The self-commercialization of Zaynich is expected to enhance Wockhardt's revenue potential and support local healthcare needs.
Advertisement
In-Article Ad
Reader Poll
What do you think about Wockhardt's decision to self-commercialize Zaynich?
Connecting to poll...
More about Wockhardt
Corporate Developments: Hyundai and Bajaj Exports Surge; Rupee Strengthens
Moneycontrol • Jun 1, 2026
Key Stocks to Monitor on June 1: Cyient, Wockhardt, IndiGo and More
News 18 • Jun 1, 2026
आज के लिए प्रमुख शेयर: SBI Life, Wockhardt, Lupin और PB Fintech पर निवेशकों की नजर
Business Standard • Jun 1, 2026
Read the original article
Visit the source for the complete story.